drugset / Trial / NCT04361032
Assessment of Efficacy and Safety of Tocilizumab Compared to DefeROxamine, Associated With Standards Treatments in COVID-19 (+) Patients Hospitalized In Intensive Care in Tunisia
Phase 3
Unknown
260 enrolled
Abderrahmane Mami Hospital
Datametrix · collabEshmoun Clinical Research Center · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
Assessment of Efficacy and Safety of Tocilizumab Compared to DefeROxamine, associated with standards treatments in COVID-19 (+) patients, Hospitalized In Intensive care in Tunisia. Multicentric, comparative, randomized study.
Timeline
- Start
- 2020-09-04
- Primary completion
- 2020-09-04
- Completion
- 2020-10-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Deferoxamine | Other / unclassified | 40 mg/kg | Intravenous |
| Subject | Tocilizumab | Monoclonal antibody | 8 mg/kg | — |